Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2008-05-06
2008-05-06
Vivlemore, Tracy (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C536S023100, C536S024500, C536S025300
Reexamination Certificate
active
07368436
ABSTRACT:
It has been determined that antisense therapy which reduces the expression of TRPM-2provides therapeutic benefits in the treatment of cancer, particularly prostate and renal cell cancers. Addition of antisense TRPM-2ODN to prostatic tumor cells in vivo is effective for delaying the onset of androgen independence, thus prostate cancer can be treated by initiating androgen-withdrawal to induce apoptotic cell death of prostatic tumor cells in an individual, and administering a composition effective to inhibit expression of TRPM-2by the tumor cells. Combined use of antisense TRPM-2and taxanes synergistically enhances cytotoxic chemosensitivity of androgen-independent prostate cancer and in human Renal cell cancer. Radiation sensitivity is also enhanced when cells expressing TRPM-2are treated with antisense TRPM-2ODN. Thus, the antisense TRPM-2ODNs can be used to enhance hormone sensitivity, chemosensitivity and radiation sensitivity of a variety of cancer types in which expression of TRPM-2has been observed.
REFERENCES:
patent: 5563255 (1996-10-01), Monia et al.
patent: 5646042 (1997-07-01), Stinchcomb et al.
patent: 5789389 (1998-08-01), Tarasewicz et al.
patent: 5801154 (1998-09-01), Baracchini et al.
patent: 5877309 (1999-03-01), McKay et al.
patent: 5929040 (1999-07-01), Werther et al.
patent: 5945290 (1999-08-01), Cowsert
patent: 5998148 (1999-12-01), Bennett et al.
patent: 6172216 (2001-01-01), Bennett et al.
patent: 6335194 (2002-01-01), Bennett et al.
patent: 6383808 (2002-05-01), Monia
patent: WO 00/49937 (2000-08-01), None
patent: WO 01/46455 (2001-06-01), None
patent: WO 02/22635 (2002-03-01), None
patent: WO 03/062421 (2003-07-01), None
patent: WO 03/072591 (2003-09-01), None
Wong et al. European Journal of Biochemistry 1994, vol. 221, pp. 917-925.
EMBL accession No. M63376, created Jul. 1991.
Buttyan et al., “Induction of the TRPM-2 Gene in Cells Undergoing Programmed Death”Molecular and Cellular BiologyAug. 1989, vol. 9, No. 8, pp. 3473-3481.
Millar et al., “Localization of mRNAs by in-situ hybridization to the residual body at stages IX-X of the cycle of the rat seminiferous epithelium: fact or artefact?”International Journal of Andrology, 17:149-160.
Darby et al., “Vascular Expression of Clusterin in Experimental Cyclosporine Nephrotoxicity”Exp Nephrol1995; 3:234-239.
Milner et al., “Selecting effective antisense reagents on combinatorial oligonucleotide arrays”Nature Biotechnologyvol. 15, Jun. 1997, pp. 537-541.
Sensibar et al., “Prevention of Cell Death Induced by Tumor Necrosis Factor alpha in LNCaP Cells by Overexpression of Sulfated Glycoprotein-2 (Clusterin),”Cancer Research. Jun. 1, 1995, vol. 55, pp. 2431-2437.
Miyake et al., “Testosterone-repressed Prostate Message-2 Is an Antiapoptotic Gene Involved in Progression to Androgen Independence in Prostate Cancer”,Cancer Research 60, Jan. 1, 2000, pp. 170-176.
Yang et al., “Nuclear clusterin/XIP8, an x-ray-induced Ku70-binding protein that signals cell death”,Proc. Nat'l Acad. Sci. USA, vol. 97, Issue 11, pp. 5907-5912, May 23, 2000.
Benner, et al., “Combination of Antisense Oligonucleotide and Low-Dose Chemotherapy in Hematological Malignancies”,Journal of Pharmacological and Toxicological Method, 37:229-235 (1997).
Nör et al.; Up-Regulation of Bcl-2 in Microvascular Endothelial Cells Enhances Intratumoral Angiogenesis and Accelerates Tumor Growth; Cancer Research; vol. 61; Mar. 1, 2001; 2183-2188.
Kirby et al.; Bartonella-Associated Endothelial Proliferation Depends on Inhibition of Apoptosis; PNAS; vol. 99, No. 7; Apr. 2, 2002; 4656-4661.
Cox et al.; Angiogenesis and Non-Small Cell Lung Cancer; Lung Cancer; vol. 27, 2000; 81-100.
Tran et al.; A Role for Survivin in Chemoresistance of Endothelial Cells Mediated by VEGF; PNAS; vol. 99, No. 7; Apr. 2, 2002; 4349-4354.
Nör et al.; Engineering and Characterization of Functional Human Microvessels in Immunodeficient Mice; Laboratory Investigation; vol. 81, No. 4; Apr. 2001; 453-463.
Boral et al.; Clinical Evaluation of Biologically Targeted Drugs: Obstacles and Opportunities; Cancer Chemother Pharmacol; vol. 42; 1998; S3-S21.
Zwain et al.; Clusterin Protects Granulosa Cells from Apoptotic Cell Death During Follicular Atresia; Experimental Cell Research; vol. 257; 2000, 101-110.
Lee et al.; In Vitro Models of Prostate Apoptosis: Clusterin as an Antiapopotic Mediator; The Prostate Supplement; vol. 9; 2000, 21-24.
Genta Incorporated; New Data Reaffirm Genta's Molecular Target as Critical Factor for Enhancing Anticancer Treatment; www.genta.com: 2001.
Gleave et al., Use of Antisense Oligonucleotides Targeting the Antiapoptotic Gene, Clusterin/Testosterone-Repressed Prostate Message 2 to Enhance Androgen Sensitivity and Chemosensitivity in Prostate Cancer, Urology, 2001, pp. 39-49, vol. 58, XP-002262320.
Gleave et al., Antisense therapy: Current status in prostate cancer and other malignancies, Cancer and Metastasis Reviews, 2002, pp. 79-92, vol. 21, XP-001147871.
Gleave et al., Targeting anti-apoptotic genes upregulated by androgen withdrawal using antisense oligonucleotides to enhance androgen- and chemo-sensitivity in prostate cancer, Investigational New Drugs, 2002, pp. 145-158, vol. 20, No. 2, XP 009021411.
Gleave et al., Antisense Targets to Enhance Hormone and Cytotoxic Therapies in Advanced Prostate Cancer, Current Drug Targets, 2003, pp. 209-221, vol. 4.
Jones et al., Molecules in focus: Clusterin, The International Journal of Biochemistry & Cell Biology, 2002, pp. 427-431, vol. 34, XP002262319.
Miyake et al., Antisense TRPM-2 Oligodeoxynucleotides Chemosensitize Human Androgen-independent PC-3 Prostate Cancer Cells Both in Vitro and in Vivo, Clinical Cancer Research, 2000, pp. 1655-1663, vol. 6, No. 5, Publisher: The American Association for Cancer Research, US, XP000960694.
Miyake et al., Synergistic Chemsensitization and Inhibition of Tumor Growth and Metastasis by the Antisense Oligodeoxynucleotide Targeting Clusterin Gene in a Human Bladder Cancer Model, Clinical Cancer Research, 2001, pp. 4245-4252, vol. 7.
Miyake et al., Novel therapeutic strategy for advanced prostate cancer using antisense oligodeoxynucleotides targeting antiapoptotic genes upregulated after androgen withdrawal to delay androgen-independent progression and enhance chemosensitivity, International Journal of Urology, 2001, pp. 337-349, vol. 8, No. 7, XP002262321.
Rosenberg et al., Clusterin: Physiologic and Pathophysiologic Considerations, Int. J. Biochem. Cell Biol., 1995, pp. 633-645, vol. 27, No. 7, XP001002844.
Wilson et al., Clusterin is a secreted mammallan chaperone, TIBS, 2000, pp. 95-98, vol. 25, XP 4202536A.
Wong et al., Molecular characterization of human TRPM-2/clusterin, a gene associated with sperm maturation, apoptosis and neurodegeneration, European Journal of Biochemistry, 1994, pp. 917-925, vol. 227, No. 3, XP 001146404.
Zangemeister-Wittke et al., A Novel Bispecific Antisense Oligonucleotide Inhibiting Both bcl-2 and bcl-xL Expression Efficiently Induces Apoptosis in Tumor Cells, Clinical Cancer Research, 2000, pp. 2547-2555, vol. 6, XP-002241562.
Zellweger et al., Antitumor Activity of Antisense Clusterin Oligonucleotides is Improved in Vitro and in Vivo by Incorporation of 2′O-(2-Methoxy)Ethyl Chemistry, The Journal of Pharmacology and Experimental, 2001, pp. 934-940, vol. 298, No. 3, XP-002262318.
Zellweger et al., Chemosensitization of Human Renal Cell Cancer Using Antisense Oligonucleotides Targeting the antiapoptotic Gene Clusterin, Neoplasia, 2001, pp. 360-367, vol. 3, No. 4.
Agrawal et al., Antisense Therapeutics: is it as simple as complementary base recognition, Molecular Medicine Today, 2000, pp. 72-81, vol. 5, Publisher: Elsevier Science Ltd.
Andrea D. Branch, A good antisense molecule is hard to find, TIBS, 1998, pp. 45-50, Publisher: Elsevier Science Ltd.
Crooke et al., Basic Principles of Antisense Therapeutics, Antisense Research and Application, 2004, pp. 1-50, Publisher: Springer.
Jen et al., Suppression of Gene Expre
Gleave Martin
Miyake Hideaki
Nelson Colleen
Rennie Paul S.
Marina Larson & Associates LLC
The University of British Columbia
Vivlemore Tracy
LandOfFree
TRPM-2 antisense therapy does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with TRPM-2 antisense therapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and TRPM-2 antisense therapy will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2810936